

Zynex Recognized in Top 100 Public Companies by ColoradoBiz

ENGLEWOOD, Colo., May 23, 2018 /[PRNewswire](#)/ -- **Zynex** (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurodiagnostic equipment, today announced that ColoradoBiz Magazine has recognized Zynex as a Top100 Public Company in its May/June 2018 issue.

Zynex was ranked 83rd on 2017 revenue of \$23.4 million up from 90th in 2016 on \$13.3 million in revenue. Adjusted EBITDA in 2017 was \$9.5 million. The company previously estimated its second quarter 2018 revenue of \$7.5 to \$8.0 million and adjusted EBITDA between \$2.5 and \$3.0 million.

About ColoradoBiz

For over 45 years, state officials, company executives and business professionals have looked to ColoradoBiz as the statewide voice of our business community. We are committed not only to highlighting the people, products, and companies that drive the economic future of our state, but helping Colorado businesses connect with each other and market themselves more effectively.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

SOURCE Zynex

For further information: Zynex, Inc., (303) 703-4906, Investor Relations Contact: Amato And Partners, LLC, Investor Relations Counsel, admin@amatoandpartners.com, Source: Zynex, Inc.

<https://zynexmed.investorroom.com/2018-05-23-Zynex-Recognized-in-Top-100-Public-Companies-by-ColoradoBiz>